Breast implant rippling evidence concerns folds in an implant shell that can be felt, seen in certain positions, or visible at rest. “Wrinkling” is often used for the implant folds themselves, while “rippling” describes their visible or palpable expression through the overlying tissues. The terms are sometimes used interchangeably, and the clinical distinction matters less than a careful assessment of location, severity, tissue coverage, implant position and the patient’s own concern.
This review focuses on primary cosmetic breast augmentation. It identifies reconstruction evidence when it is used, because a mastectomy skin envelope, radiotherapy, expanders and acellular dermal matrices create a different problem from an unoperated cosmetic breast. Available evidence is largely observational, so neither a filler, surface nor pocket can be presented as a guaranteed way to prevent rippling.
What rippling looks and feels like
Some implant edges or folds are palpable without being visible, particularly in the lower outer breast or cleavage area. Others appear only when a person leans forward, raises the arms or changes muscle tension. More conspicuous rippling can be visible while standing at rest. A 2018 review proposed a simple descriptive scale: Grade 1 for palpable but invisible rippling, Grade 2 for visibility only on forward bending and Grade 3 for upright visibility. It is useful language for a consultation, but it is not a validated personal-risk calculator.
New contour changes should not automatically be called rippling. Malposition, capsular contracture, fluid collection, implant deflation or rupture, weight change and normal healing can alter breast shape. A sudden unilateral change, significant pain, swelling or redness requires clinical assessment. A photograph sent online cannot reliably distinguish implant folds from a complication.
Why folds become visible
An implant is a flexible shell containing saline or silicone gel. Its surface can form folds when it moves within a pocket or when soft tissue presses unevenly on it. Whether those folds become perceptible depends substantially on the thickness and quality of tissue between the implant and the skin. Low subcutaneous coverage, a thin breast envelope, a wide pocket relative to the implant and changes in body weight can make the same implant more apparent in one person than another.
Implant size is not a simple answer. A larger implant may alter tension and coverage, while a smaller implant can leave a redundant pocket or less soft-tissue support in a different setting. Implant dimensions must fit breast base width, tissue characteristics, skin elasticity, chest wall shape and patient goals. The evidence review of implant dimensions, base width and cc explains why volume is not a reliable proxy for an individual result.
Filler and cohesivity
Saline and silicone gel implants differ in how the filler moves inside the shell. Clinicians often describe more cohesive gel implants as holding their shape more consistently, which may make folds less apparent in selected situations. That plausible mechanical rationale does not establish a universal clinical advantage. Implant generations, shell design, surface, profile, pocket and tissue coverage commonly vary together in published series, making filler effects difficult to isolate.
Older core-data reviews discuss rippling alongside other device outcomes, but they do not provide a head-to-head answer for every modern implant choice. The FDA’s current breast-implant information is essential for discussing recognised device risks and follow-up, yet it does not endorse one filler as a rippling-prevention device. The appropriate discussion is therefore comparative and anatomical: what trade-offs may matter in this breast, and what evidence is actually direct?
Pocket placement and coverage
Pocket choice changes the tissue layers over an implant. In a subglandular plane, the upper pole may have less muscular coverage, which can make edge visibility more apparent in a thin envelope. A subpectoral or dual-plane relationship can add muscle coverage over part of the implant, but it also introduces possible dynamic distortion, animation deformity and displacement. A single-surgeon observational report found less superior-pole rippling after subpectoral than subglandular augmentation, while noting trade-offs in muscle-related deformity and migration. That is hypothesis-generating rather than proof of a best pocket.
Subfascial placement is sometimes proposed as an intermediate option. The fascia is thin and its coverage effect is variable, so its value cannot be assumed from its name. Pocket selection should not be driven by a promise to hide rippling; it is a broader decision about tissue coverage, breast shape, muscle function and the patient’s priorities. See the research review of implant pocket placement for this wider evidence base.
Surface is not a simple rippling solution
Textured surfaces were historically discussed as a way to increase tissue adherence and reduce movement. Contemporary decision-making is more complex because surfaces have different safety considerations, including the BIA-ALCL association with textured devices. A 2026 systematic review and meta-analysis of textured versus smooth implants found no significant pooled difference in rippling, despite analysing cosmetic augmentation and reconstruction cohorts. Its mixed populations and study designs limit certainty, but it is a useful warning against claiming that texture reliably prevents folds.
Surface choice must therefore be considered with current regulatory information, not only with a desired contour outcome. The review of breast implant surface technology provides that wider context. A discussion about rippling should never minimise device-specific safety counselling.
Why reconstruction data need caution
Prepectoral reconstruction literature reports very variable rippling rates. A 2023 review found a range from 0 to 53.8% across 25 studies and emphasised pocket dimensions, expander fill, implant characteristics and technical modifications. Those data are valuable for understanding the role of coverage, but they cannot be converted into a cosmetic augmentation percentage. Reconstruction patients may have very thin mastectomy flaps, previous cancer treatment and added support materials; they start with a different tissue envelope.
The 2018 rippling review also includes both augmentation and reconstruction and describes fat grafting, acellular dermal matrix, capsule adjustment, implant exchange and plane change as potential management options. Its Level V evidence designation is important. These approaches may be reasonable in carefully selected revision cases, but comparative trials are limited and each additional operation has its own risks. “Fat transfer fixes rippling” or “changing the plane fixes rippling” are not evidence-based promises.
Assessment before and after augmentation
Before surgery, assessment may include skin and soft-tissue thickness, breast-base dimensions, asymmetry, chest-wall contour, skin elasticity, weight stability and the tissue available in the intended pocket. These findings support an informed conversation about what can be improved and what may remain visible or palpable. The breast augmentation treatment guide explains practical implant planning, while this article focuses on the narrower contour-evidence question.
After surgery, timing matters. Swelling, implant position and tissue adaptation evolve during early healing, so a clinician interprets rippling in context rather than treating every early fold immediately. If a contour concern persists, the surgeon evaluates whether it is a mild positional finding, inadequate coverage, pocket change, implant characteristic, contracture or another diagnosis. A revision plan may involve observation, changes in implant dimensions or filler, pocket modification, soft-tissue augmentation or a combination; no treatment should be selected from an image alone.
Body composition can also change the way an established result looks. Weight loss may reduce the soft-tissue layer over an implant, whereas pregnancy, ageing and changes in skin elasticity can alter the envelope and breast position. These observations do not mean that a patient can prevent rippling through one lifestyle action, or that every change is caused by the implant. They explain why a consultation should compare current findings with the original anatomy, operative history and the patient’s own account of when the contour changed.
It is equally important not to confuse a cosmetic contour concern with an emergency. Rippling itself is often not medically urgent, but progressive swelling, a new hard breast, marked asymmetry, systemic illness or a late fluid collection are different clinical problems. The correct response is timely assessment by an appropriately qualified clinician, with imaging or further investigation when indicated—not self-diagnosis from social-media photographs or a generic revision recommendation.
Questions that improve informed consent
Patients can ask: How much tissue coverage do I have in the areas where rippling tends to show? How does the proposed pocket affect coverage and movement? What is known—and not known—about the selected implant’s filler and surface? Which contour changes may be visible only in certain positions? If rippling becomes bothersome, how would it be assessed and what are the trade-offs of revision?
For plain-language preparation and recovery questions, see the breast augmentation safety guide. Related evidence includes implant malposition patterns and round versus anatomical implant design. These resources inform questions; they do not replace examination or individualised surgical advice.
Limitations and conclusion
Breast implant rippling evidence is limited by mixed definitions, subjective assessment, retrospective case series and the frequent blending of cosmetic and reconstruction populations. Techniques and devices change together, while patient anatomy influences both selection and outcome. Even comparative evidence cannot tell an individual whether a fold will be visible in a particular position years after surgery.
The most defensible conclusion is anatomical rather than promotional. Rippling becomes more noticeable when implant folds have less stable soft-tissue coverage, but filler, size, shell, surface and pocket interact with that coverage. Careful planning can reduce avoidable mismatch and support honest expectations; it cannot eliminate every contour trade-off. A new or concerning change deserves examination, and any revision decision should weigh the potential benefit against the risks and limitations of another operation.